Sequence motifs associated with hepatotoxicity of locked nucleic acid - Modified antisense oligonucleotides

Nucleic Acids Research

Volumn 42, Issue 8, 2014, Pages 4882-4891

  Burdick, Andrew D ^a   Sciabola, Simone ^a   Mantena, Srinivasa R ^a   Hollingshead, Brett D ^a   Stanton, Robert ^a   Warneke, James A ^a   Zeng, Ming ^b   Martsen, Elena ^b   Medvedev, Alexander ^b   Makarov, Sergei S ^b   Reed, Lori A ^a   Davis, John W ^a   Whiteley, Laurence O ^a  

^a PFIZER INC   (United States)

^b Attagene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUTAMATE DEHYDROGENASE; LOCKED NUCLEIC ACID; LOCKED NUCLEIC ACID MODIFIED ANTISENSE OLIGONUCLEOTIDE; PROTEIN P53; TRANSCRIPTION FACTOR NRF2; TROPONIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MACHINE LEARNING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE MOTIF; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN STRUCTURE; SENSITIVITY AND SPECIFICITY; STRESS; TCC MOTIF; TGC MOTIF; TRANSCRIPTION INITIATION;

ANIMALS; LIVER; MALE; MICE; NF-E2-RELATED FACTOR 2; NUCLEOTIDE MOTIFS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899807328     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gku142     Document Type: Article

References (26)

1. Stein, C.A., Subasinghe, C., Shinozuka, K. and Cohen, J.S. (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res., 16, 3209-3221.
2. Cummins, L.L., Owens, S.R., Risen, L.M., Lesnik, E.A., Freier, S.M., McGee, D., Guinosso, C.J. and Cook, P.D. (1995) Characterization of fully 2′-modified oligoribonucleotide hetero-and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res., 23, 2019-2024.
3. Sazani, P., Astriab-Fischer, A. and Kole, R. (2003) Effects of base modifications on antisense properties of 2′-O-methoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev., 13, 119-128.
4. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hokfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K. et al. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA, 97, 5633-5638.
5. Jepsen, J.S., Sorensen, M.D. and Wengel, J. (2004) Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides, 14, 130-146.
6. Burnett, J.C. and Rossi, J.J. (2012) RNA-based therapeutics: current progress and future prospects. Chem. Biol., 19, 60-71.
7. Koshkin, A., Rajwanshi, V. and Wengel, J. (1998) Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides. Tetrahedron Lett., 39, 4381-4384.
8. Koshkin, A., Singha, S., Nielsenb, P., Rajwanshia, V., Kumara, R., Meldgaarda, M., Olsenc, C. and Wengel, J. (1998) LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recogn. Tetrahedron, 54, 3607-3630.
9. Obika, S., Nanbu, D., Hari, Y., Andoh, J., Morio, K., Doi, T. and Imanishi, T. (1998) Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O, 4′-C-methyleneribonucleosides. Tetrahedron Lett., 30, 5401-5404.
10. Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., Walters, E., Kreeger, J., DiMattia, D., Chen, T. et al. (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther., 22, 344-359.
11. Greenberger, L., Horak, I., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H., Albæk, C., Schrøder, H. and Ørum, H. (2008) A RNA antagonist of hypoxia-inducible factor-1A, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther., 7, 3598-3608.
12. Akdim, F., Visser, M., Tribble, D., Baker, B., Stroes, E., Yu, R., Flaim, J., Su, J., Stein, E. and Kastelein, J. (2010) Effect of Mipomersen, an Apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol., 105, 1413-1419.
13. Raal, F., Santos, R., Blom, D., Marais, A., Charng, M., Cromwell, W., Lachmann, R., Gaudet, D., Tan, J., Chasan-Taber, S. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 375, 998-1006.
14. Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., Kauppinen, S. and Orum, H. (2010) Therapeutic silencing of microRNA-122 in primates with chronic Hepatitis C virus infection. Science, 327, 198-201.
15. Hildebrandt-Eriksen, E.S., Aarup, V., Persson, R., Hansen, H.F., Munk, M.E. and Orum, H. (2012) A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther., 22, 152-161.
16. Petersen, M., Nielsen, C.B., Nielsen, K.E., Jensen, G.A., Bondensgaard, K., Singh, S.K., Rajwanshi, V.K., Koshkin, A.A., Dahl, B.M., Wengel, J. et al. (2000) The conformations of locked nucleic acids (LNA). J. Mol. Recognit., 13, 44-53.
17. Swayze, E.E., Siwkowski, A.M., Wancewicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., Hung, G., Monia, B.P. and Bennett, C.F. (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res., 35, 687-700.
18. Hagedorn, P.H., Yakimov, V., Ottosen, S., Kammler, S., Nielsen, N.F., Hog, A.M., Hedtjarn, M., Meldgaard, M., Moller, M.R., Orum, H. et al. (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther., 23, 302-310.
19. Breiman, L. (2001) Random forests. Mach. Learn., 45, 5-32.
20. Liaw, A. and Wiener, M. (2002) Classification and regression by random forest. R. News, 2, 18-22.
21. Burdelya, L.G., Brackett, C.M., Kojouharov, B., Gitlin, I.I., Leonova, K.I., Gleiberman, A.S., Aygun-Sunar, S., Veith, J., Johnson, C., Haderski, G.J. et al. (2013) Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc. Natl Acad. Sci. USA, 110, E1857-E1866.
22. Liu, F., Song, Y. and Liu, D. (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther., 6, 1258-1266.
23. Zhang, G., Budker, V. and Wolff, J.A. (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther., 10, 1735-1737.
24. Romanov, S., Medvedev, A., Gambarian, M., Poltoratskaya, N., Moeser, M., Medvedeva, L., Gambarian, M., Diatchenko, L. and Makarov, S. (2008) Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat. Methods, 5, 253-260.
25. Cuddihy, A.R., Li, S., Tam, N.W., Wong, A.H., Taya, Y., Abraham, N., Bell, J.C. and Koromilas, A.E. (1999) Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol. Cell. Biol., 19, 2475-2484.
26. Sadler, A.J. and Williams, B.R. (2008) Interferon-inducible antiviral effectors. Nat. Rev. Immunol., 8, 559-568.